Search

Mirati Therapeutics Inc

Lezárt

SzektorEgészségügy

0

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

Maximum

Ajánlások

By TipRanks

Ajánlások

Semleges

12 hónapos előrejelzés

-0.05% downside

Hangulat hírek alapján

By Acuity

50%

50%

128 / 340 Rangsor szerint Healthcare

Mirati Therapeutics Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 8. 00:06 UTC

Event
News

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are trading higher in after-market hours.

2026. aug. 8. 00:02 UTC

News

Eli Lilly shares are higher in after-market trading following FDA filing plans for retatrutide, a potential competitor in the weight-loss market.

2026. aug. 8. 00:02 UTC

Social Media
News

Cloudflare Inc. shares are trading higher after a strong earnings report, with revenue up 36% and upwardly revised full-year guidance. TD Cowen raised its price target to $355.

2026. aug. 8. 00:02 UTC

News

Celsius Holdings Inc shares are lower in after-market hours following an investigation into potential securities law violations and disappointing second-quarter revenue.

2026. aug. 8. 00:02 UTC

News

Dropbox shares are higher in after-hours trading following Citigroup's price target increase to $33, maintaining a Neutral rating on the stock.

2026. aug. 8. 00:01 UTC

News

Citigroup raised its price target for Cognex Corp to $74, maintaining a Neutral rating. Shares are higher in after-market hours, recovering from recent losses.

2026. aug. 8. 00:01 UTC

News

UBS raised its price target on Howmet Aerospace to $326. Shares are trading higher in after-market hours following the report.

2026. aug. 8. 00:01 UTC

News

Mitek Systems reported an 18% revenue increase in Q3, driven by strong SaaS growth. Shares rose after-market, settling higher since Friday's close.

2026. aug. 7. 23:56 UTC

News

Sweetgreen shares declined in after-market trading as multiple analysts lowered price targets, with UBS and RBC both setting targets at $6.50.

2026. aug. 7. 23:46 UTC

News

JetBlue Airways reports wider net loss and updates operating guidance. Shares are lower in after-market trading following the $121.4 million shelf registration.

2026. aug. 7. 23:46 UTC

News

Etsy Inc shares are lower in after-market hours following its Q2 results, which showed a double beat but faced revenue challenges from divestments.

2026. aug. 7. 23:46 UTC

News

Cogent Communications is trading lower in after-market hours amid a class action lawsuit alleging securities fraud by Pomerantz LLP and ongoing operational challenges.

2026. aug. 7. 23:41 UTC

News

ResMed shares declined after-market despite RBC Capital raising its price target to $244 and maintaining a Sector Perform rating.

2026. aug. 7. 23:41 UTC

News

Mitek Systems reported an 18% revenue increase in Q3, with shares advancing in after-market hours, despite earlier pulling back from a session high.

2026. aug. 7. 23:36 UTC

News

Tripadvisor Inc announced participation in two investor conferences, enhancing engagement with investors. Shares are trading slightly higher in after-market hours.

2026. aug. 7. 23:36 UTC

News

Shift4 Payments lowers 2026 outlook, adjusting full-year revenue guidance down by about 200 basis points. Shares are trading lower in after-market hours.

2026. aug. 7. 23:36 UTC

News

Epam Systems shares are trading lower in after-market hours following TD Cowen's price target cut to $120, despite earlier gains in the session.

2026. aug. 7. 23:31 UTC

News

Arcutis Biotherapeutics granted 143,500 RSUs and options to new hires. Shares are trading higher in after-market hours following the announcement.

2026. aug. 7. 23:31 UTC

News

Figs Inc reported strong Q2 earnings but is trading lower in after-market hours as Telsey Advisory Group lowered its price target to $16.

2026. aug. 7. 23:31 UTC

News

Ardelyx shares are higher in after-market trading as TD Cowen maintains a Buy rating and lowers the price target to $10.

2026. aug. 7. 23:31 UTC

News

Celsius Holdings is under investigation for potential securities law violations following disappointing second-quarter results, with shares trading lower in after-market hours.

2026. aug. 7. 23:26 UTC

News

Delta Air Lines is gaining after reporting strong second-quarter results and positive passenger traffic growth projections, with anticipated earnings of $6.63 per share.

2026. aug. 7. 23:26 UTC

News

Five9 Inc. reported second-quarter earnings of $0.70 per share and raised full-year revenue guidance to $1.27 billion. Shares are higher in after-market trading.

2026. aug. 7. 23:26 UTC

News

UBS raised its price target on Unity Software Inc. to $48, contributing to shares trading higher in after-market hours. Positive sentiment from tech stocks also supported this move.

2026. aug. 7. 23:26 UTC

Event
News

Scholar Rock Holding Corp reports FDA review progress for apitegromab, with a decision expected by September 30, 2026. Shares are trading higher in after-market hours.

2026. aug. 7. 23:26 UTC

News

Kraft Heinz Co reported second-quarter revenue of $6.26 billion, exceeding expectations. Shares rose in after-market trading amid positive sentiment and broader market strength.

2026. aug. 7. 23:26 UTC

News

Leidos Holdings shares are lower in after-market hours after TD Cowen raised the price target to $135 while maintaining a Hold rating.

2026. aug. 7. 23:21 UTC

News

MP Materials will participate in Canaccord Genuity's Growth Conference in August 2026. Shares are trading higher in after-market hours following the announcement.

2026. aug. 7. 23:21 UTC

News

TD Cowen raised its price target on Akamai Technologies to $140 while maintaining a Hold rating. Shares are higher in after-market trading.

2026. aug. 7. 23:21 UTC

Social Media
News
Event

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are sharply higher in after-market trading amid positive investor sentiment.

Társak összehasonlítása

Árváltozás

Mirati Therapeutics Inc Előrejelzés

Célár

By TipRanks

-0.05% elmozdulás lefelé

12 hónapos előrejelzés

Átlag 58.67 USD  -0.05%

Magas 59 USD

Alacsony 58 USD

5 Wall Street elemző 12 hónapos célárain alapulva a(z)Mirati Therapeutics Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Semleges

5 ratings

0

Vétel

5

Tartás

0

Eladás

Hangulat

By Acuity

128 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Neutral

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

EBITDA

Üzemi nyereség

$

Rólunk Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.
help-icon Live chat